Skip to main content

EFECTOS FUNCIONALES Y MOLECULARES DE DISTINTAS FORMAS DE HDL EN EL REMODELADO CARDIACO POST-INFARTO: APLICACION DE BIOLOGIA DE SISTEMAS PARA IDENTIFICAR LAS DIANAS MOLECULARES

SAF2012-40208

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2012
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre CONSORCI INSTITUT CATALA DE CIENCIES CARDIOVASCULARS DE CIENCIES CARDIOVASCULARS (ICCC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A novel truncated form of apolipoprotein A-I transported by dense LDL is increased in diabetic patients

  • Cubedo, Judit|||0000-0003-3291-9137
  • Padró, Teresa|||0000-0003-1921-954X
  • García-Arguinzonis, Maisa|||0000-0001-6749-5026
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Miñambres, Inka|||0000-0002-0899-3938
  • Pou, Josep Maria
  • Ybarra, Juan
  • Badimon, Lina|||0000-0002-9162-2459
Diabetic (DM) patients have exacerbated atherosclerosis and high CVD burden. Changes in lipid metabolism, lipoprotein structure, and dysfunctional HDL are characteristics of diabetes. Our aim was to investigate whether serum ApoA-I, the main protein in HDL, was biochemically modified in DM patients. By using proteomic technologies, we have identified a 26 kDa ApoA-I form in serum. MS analysis revealed this 26 kDa form as a novel truncated variant lacking amino acids 1-38, ApoA-IΔ(1-38). DM patients show a 2-fold increase in ApoA-IΔ(1-38) over nondiabetic individuals. ApoA-IΔ(1-38) is found in LDL, but not in VLDL or HDL, with an increase in LDL3 and LDL4 subfractions. To identify candidate mechanisms of ApoA-I truncation, we investigated potentially involved enzymes by in silico data mining, and tested the most probable molecule in an established animal model of diabetes. We have found increased hepatic cathepsin D activity as one of the potential proteases involved in ApoA-I truncation. Cathepsin D-cleaved ApoA-I exhibited increased LDL binding affinity and decreased antioxidant activity against LDL oxidation. In conclusion, we show for the first time: a) presence of a novel truncated ApoA-I form, ApoA-IΔ(1-38), in human serum; b) ApoA-IΔ(1-38) is transported by LDL; c) ApoA-IΔ(1-38) is increased in dense LDL fractions of DM patients; and d) cathepsin D-ApoA-I truncation may lead to ApoA-IΔ(1-38) binding to LDLs, increasing their susceptibility to oxidation and contributing to the high cardiovascular risk of DM patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lipidomic changes of LDL in overweight and moderately hypercholesterolemic subjects taking phytosterol- and omega-3-supplemented milk

  • Padró, Teresa|||0000-0003-1921-954X
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Sánchez-Hernández, Joan
  • Hernández García, Marta|||0000-0003-1237-298X
  • Antonijoan Arbós, Rosa Ma|||0000-0002-7099-5125
  • Pérez, Antonio|||0000-0001-5528-1143
  • Badimon, Lina|||0000-0002-9162-2459
The benefits of dietary phytosterols (PhySs) and long-chain n-3 PUFA (ω3) have been linked to their effects as cholesterol- and triglyceride (TGL)-lowering agents. However, it remains unknown whether these compounds have further metabolic effects on LDL lipid composition. Here, we studied the effects of PhyS- or ω3-supplemented low-fat milk (milk) on the LDL-lipidome. Overweight and moderately hypercholesterolemic subjects (n = 32) were enrolled in a two-arm longitudinal crossover study. Milk (250 ml/day), enriched with either 1.57 g PhyS or 375 mg ω3 (EPA + DHA), was given to the participants during two sequential 28 day intervention periods. Compared with baseline, PhyS-milk induced a higher reduction in the LDL cholesterol (LDLc) level than ω3-milk. LDL resistance to oxidation was significantly increased after intervention with PhyS-milk. Changes in TGL and VLDL cholesterol were only evident after ω3-milk intake. Lipidomic analysis revealed a differential effect of the PhyS- and ω3-milk interventions on the LDL lipid metabolite pattern. Content in LDL-glycerophospholipids was reduced after PhyS-milk intake, with major changes in phosphatidylcholine (PC) and phosphatidylserine subclasses, whereas ω3-milk induced significant changes in the long-chain polyunsaturated cholesteryl esters and in the ratio PC36:5/lysoPC16:0, associated to a reduced inflammatory activity. In conclusion, daily intake of milk products containing PhyS or ω3 supplements induce changes in the LDL-lipidome that indicate reduced inflammatory and atherogenic effects, beyond their LDLc- and TGL-lowering effects.